Celularity
FLORHAM PARK, NJ · Biotechnology · 162 employees
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through n
Funding history
- Funding Round — $2.0M — Nov 2025
- Series seed — $1.0M — Aug 2025
- Series seed — $2.0M — Aug 2025
- Funding Round — $6.8M — Aug 2025
- Funding Round — $30.0M — May 2022
Recent signals
- Jun 03, 2026: Celularity Inc. Appoints Rick Gonzalez as Chief Commercial Officer
- Mar 05, 2026: Celularity Inc. Appoints John Sprague as Acting Chief Financial Officer
- Feb 27, 2026: SEC 8-K (5.02): On February 27, 2026, Joseph DosSantos departed from his role as the Senior Vice President of Finance and Acting Chief Financial Officer of Celularity Inc. for personal reasons. Concurrently on the same date, John Sprague was appointed as the Acting Chief Financial Officer of the Company. This change in leadership could impact the financial strategy and oversight of Celularity Inc., especially considering the responsibilities associated with the CFO position during a critical phase in the company's operations.
- Nov 03, 2025: Raised $2.0M
- Aug 05, 2025: Raised $1.0M in Series seed
- Aug 05, 2025: Raised $2.0M in Series seed
- Aug 05, 2025: Raised $6.8M
- Jul 09, 2025: Celularity Partners with Fountain Life to Provide Stem Cell Therapies in Florida.
See plans & pricing → Track Celularity’s funding, hiring, and signals — with verified contacts — on Fundz.